Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMBITION: Biomarker-driven Targeted Therapy in Platinum-resistant Ovarian Cancer
NCT03699449Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Nov 2018
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, olaparib, cediranib, tremelimumab in ovarian cancer, sponsored by Yonsei University. Status: unknown.
02
Drugs
durvalumabolaparibcediranibtremelimumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT03699449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699449.